Fei Shen

Fei received her Ph.D. in Neuropharmacology from Loyola University Chicago Stritch School of Medicine and a B.Sc in Biochemistry from East China University Science & Technology. In 2007, she started her industrial career at Theravance Biopharma as an in vivo pharmacologist and led a lab in driving multiple research projects from exploratory, lead optimization to development candidate nomination, including TD-1473 in Ulcerative Colitis, Ampreloxetine in Fibromyalgia, Velusetrag in Gastroparesis, TD-8954 in Post-operative Gastrointestinal Dysfunction. In 2015, she joined Boehringer Ingelheim Pharmaceuticals Inc. Global Immunology and Respiratory Disease Research in Ridgefield where she started as a Laboratory Head and became the Head of in vivo Pharmacology group in 2016. From 2015 to 2020, before joining the BI Venture Fund, Fei led a group of ~20 in vivo pharmacologists supporting the Immunology and Respiratory Portfolio for small molecule, antisense and antibody projects.